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The last two decades have deepened our understanding
of the biology of melanoma in signiﬁcant new directions.
This progress has resulted in the development of thera-
peutics with unprecedented clinical potential. Ipilimumab
and tremelimumab are anti-CTLA4 monoclonal antibodies
that alter the regulatory immune network responsible for
damping anticancer immune responses, and this class of
agent has shown the ﬁrst signiﬁcant impact upon survival
of metastatic melanoma. Meanwhile, agents that inhibit
activating mutations that drive the oncogenic processes such
as B-RAF or c-KIT have shown clear eﬀectiveness and
almost immediate responses. It remains uncertain how the
current individual treatments work at the level of the tumor
during treatment. Moreover, the weight that the genetic
background of the host may have in relation to treatment
response has yet to be explored. A lot still needs to be done
to improve the durability of treatment beneﬁts, and cure
remains an elusive goal. The topics presented here are not an
exhaustive representation of the ﬁeld of melanoma research,
but a sampling of the large and many-faceted agenda of
current interest that we have the pleasure of sharing with
the readers. We would like to thank the authors for their
excellent contributions and patience in this venture. Finally,
the fundamental work of reviewers of the papers is also very
warmly acknowledged.
This special issue contains seven papers, three related
to epidemiology, diagnosis, risk factors, and characteris-
tics of melanoma. Two papers focus on speciﬁc disease
treatments, one using the isolated limb infusion (ILI) and
the second based on the adoptive transfer of autologous
tumor-inﬁltrating lymphocytes (TIL) for therapy of locally
or systemically advanced melanoma, respectively. Also two
papers address the management of brain metastases and
uveal melanoma.
In the paper entitled “The contribution of electron param-
agnetic resonance to melanoma research,” Q. Godechal and B.
Gallez showed how electron paramagnetic resonance (EPR),
a method able to detect free radicals trapped in melanin
pigments, has recently provided insight to basic features of
melanoma that may improve its diagnosis. These advances
may improve the diagnosis of melanoma, but the limitations
of the method are also detailed.
Thepaperentitled“Nonsteroidalanti-inﬂammatorydrugs
a n dr i s ko fm e l a n o m a ” presents a pilot study of the asso-
ciation between NSAID usage and melanoma incidence, to
determine whether epidemiologic evidence of a chemopre-
ventive eﬀect of these agents is compelling. On the basis of
the conﬂicting reports in the literature, it is suggested that
meta-analysis may better establish this possible association.
In the paper entitled “What is really risky in melanoma?
prognostic parameters for the primary care of melanoma
patients,” D. G¨ oppner and M. Leverkus reviewed the lit-
erature data and summarized current understanding of
carcinogenesis in melanoma giving a detailed overview of
known morphologic and potentially future genetic prognos-
tic parameters in malignant melanoma.
The paper entitled “Treatment of locally advanced
melanoma by isolated limb infusion with cytotoxic drugs”
overviews isolated limb infusion (ILI), as a less invasive
technique than the classical isolated limb perfusion (ILP)
which may be preferred for locally advanced melanoma
conﬁned to a limb. The minimally invasive character of
ILI may replace ILP in the future as palliation for locally
advanced limb tumors.2 Journal of Skin Cancer
In the paper entitled “Characterization of ex vivo
expanded tumor inﬁltrating lymphocytes from patients with
malignantmelanomaforclinicalapplication,” M. H. Andersen
etal.reportadiﬀerentmethodforexpandingtumorinﬁltrat-
ing lymphocytes (TIL) to clinically relevant quantities in two
steps within 8 weeks. This method may be utilized for new
clinical trials, where adoptive transfer of autologous tumor
inﬁltrating lymphocytes (TIL) has shown objective clinical
responses in up to 50% of treated patients.
In the paper entitled “Management of melanoma brain
metastases in the era of targeted therapy,” D. G. Shapiro and
W. E. Samlowski discuss approaches for melanoma brain
metastases using targeted agents combined with classical
surgery and radiosurgery, along with the possibility of
improving survival in at least a subset of melanoma patients
with brain metastases.
In the paper entitled “Uveal melanoma,” V. M. L.
Cohen and V. P. Papastefanou give a 360◦Co v e r v i e w
uveal melanoma from genetic alterations to diagnosis and
treatment.
These studies span the range of etiology and regional
as well as systemic therapy for melanoma, to provide a
background that may be useful for readers in relation to
regional and systemic metastasis, including the most omi-
nous phase of brain metastasis, which punctuate the course
of disease. The clear diﬀerences between uveal melanoma,
a disease nominally included among “the melanomas” are
now biologically recognized as diverse in histogenesis and
relevant mutational oncogenic pathways. These papers are
timely in this year of regulatory approvals for several
new agents, and the pending likelihood that new agents
will join this armamentarium for melanoma. An area not
touched upon is that of adjuvant therapy, which may provide
insights to further roles of therapy and ultimately, with
chemoprevention,maylessentheburdenofadvanceddisease
in the future.
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